US-based contract research organisation (CRO) Synteract has expanded its consulting offering to include expert advice to venture capital organisations (VCOs) funding biotechnology, medical device and pharmaceutical start-ups.

According to Synteract, many biopharmaceutical companies approach VCOs during the clinical trial phase. However, venture capitalists – even those specialising in the field – often do not possess the necessary in-house clinical expertise “to assess product development programmes for integration of sound science with the realities of the regulatory and marketing environment”.

The CRO says it can support the due diligence process by contributing:

- A comprehensive evaluation of current clinical trial programmes, either planned or in progress, with a review from clinical, regulatory, statistical, pro forma budgeting, timeline/milestone and marketing perspectives.

- An assessment of the target company’s plans for executing its clinical development programmes to achieve marketing approvals, based on thoroughness, sufficiency of resources and timing.

Synteract can also help the start-up company to understand which aspects of its studies may need assistance, the CRO notes, adding that it often designs and supports comprehensive product development programmes for its VCO-funded clients.

Established in 1995, Synteract is a privately held, full-service CRO with particular expertise in oncology, the central nervous system, cardiovascular disease and ophthalmology.